Vischer advised Mininavident, located in Liestal, a developer and manufacturer of the world’s smallest dynamic navigation system for dental implant placement, which was acquired by the Straumann Group, a global leader in tooth replacement,
Tags :Vischer
Vischer acted as Swiss legal counsel to FIT Voltaira Group – a supllier of sensor, connectivity, and electrification solutions – on the acquisition of the globally operating Auto-Kabel Group, in collaboration with the lead counsel KÜMMERLEIN
ISS Facility Services, advised by CMS, acquired gammaRenax, advised by Vischer. With the acquisition, ISS seeks to strengthen its position as a provider of comprehensive facility management services in Switzerland. CMS’ team Corporate / M&
Vischer advised BID Equity on Realview’s acquisition, a developer and software distributor for the Swiss construction industry. Founded in 2013 and based in Zurich, Realview, with it stried-and-tested software solutions, operates a decisive contribution to
Vischer advised the main investors on the extension of Memo Therapeutics’ series C financing round, raising CHF20 million and bringing the total amount raised in the funding round to CHF 45m. Vischer’s team Vischer’
by claudia la via Artificial Intelligence technology is revolutionizing the way we work, interact, and drive innovation. However, integrating AI into business processes also entails legal challenges and risks, ranging from data protection and confidentiality
Oculis Holding has completed a financing of approximately $59m, consisting of the issuance of 5,000,000 of its ordinary shares at a purchase price of $11.75 per share. A prospectus required for the listing on the Nasdaq Iceland
The Swiss dental startup Odne has raised USD 5.5m to fund the upcoming US market launch for their minimal invasive Root Preservation Technology (RPT). The Series A1 round for Odne, was led by Revere Partners (
Artiria Medical, a Swiss neurovascular MedTech company developing next-generation neuro interventional products for stroke and aneurysms, closed a USD 6m series A2 financing round. The round was led by 4FOX Ventures, with the Wyss Center
EraCal Therapeutics AG (“EraCal”), a Swiss biotech start-up company focusing on the fight of obesity, has licensed its main asset to Novo Nordisk for a total amount of EUR 235m in a collaboration and license
